Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $437.49 +0.75%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 40
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 40
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $375.00 (from $320.00) while maintaining a Outperform rating.
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Customers Bancorp (CUBI) PT Raised to $107 at DA Davidson as Stock 'Very Undervalued'
- Eli Lilly (LLY) PT Raised to $1,450 at Bernstein SocGen on 'International Upside Potential'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
